Home
/
Corbus Pharmaceuticals Holdings, Inc.
/
Financials
/
Quarterly
Corbus Pharmaceuticals Holdings, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Corbus Pharmaceuticals Holdings, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2019
Mar 31, 2019
$1.89M
May 9, 2019
Q3
2018
Sep 30, 2018
$1.09M
Nov 8, 2018
Q2
2018
Jun 30, 2018
$853.6K
Aug 8, 2018
Q1
2019
Mar 31, 2018
$950.4K
May 9, 2019
Q3
2018
Sep 30, 2017
$796.3K
Nov 8, 2018
Q2
2018
Jun 30, 2017
$350.2K
Aug 8, 2018
Q1
2018
Mar 31, 2017
$1.29M
May 10, 2018
Q3
2017
Sep 30, 2016
$742.6K
Nov 8, 2017
Q2
2017
Jun 30, 2016
$396.6K
Aug 9, 2017
Q1
2017
Mar 31, 2016
$396.6K
May 9, 2017
Q3
2016
Sep 30, 2015
$170.5K
Nov 10, 2016
Q2
2016
Jun 30, 2015
$113.6K
Aug 12, 2016
Q1
2016
Mar 31, 2015
$0
May 13, 2016
Q3
2015
Sep 30, 2014
$0
Nov 10, 2015
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2022
Sep 30, 2022
$0
Nov 8, 2022
Q1
2022
Mar 31, 2022
$0
May 10, 2022
Q3
2022
Sep 30, 2021
$97.3K
Nov 8, 2022
Q2
2022
Jun 30, 2021
$136.6K
Aug 9, 2022
Q1
2022
Mar 31, 2021
$647.8K
May 10, 2022
Q3
2021
Sep 30, 2020
$1.23M
Nov 12, 2021
Q2
2021
Jun 30, 2020
$286.3K
Aug 12, 2021
Q1
2021
Mar 31, 2020
$1.76M
May 13, 2021
Q3
2020
Sep 30, 2019
$2.59M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$29.09M
Aug 31, 2020
Q1
2020
Mar 31, 2019
$1.89M
May 11, 2020
Q3
2019
Sep 30, 2018
$1.09M
Nov 7, 2019
Q2
2019
Jun 30, 2018
$853.6K
Aug 8, 2019
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($23.34M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($17.66M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($16.98M)
May 6, 2025
Q3
2025
Sep 30, 2024
($13.78M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($10.00M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($6.90M)
May 6, 2025
Q3
2024
Sep 30, 2023
($10.05M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($8.78M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($17.74M)
May 7, 2024
Q3
2023
Sep 30, 2022
($8.78M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($13.25M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($9.44M)
May 9, 2023
Q3
2022
Sep 30, 2021
($2.18M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($17.14M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($16.07M)
May 10, 2022
Q3
2021
Sep 30, 2020
($34.90M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($38.11M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($29.66M)
May 13, 2021
Q3
2020
Sep 30, 2019
($20.79M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
$2.15M
Aug 31, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($24.42M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($19.15M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($19.78M)
May 6, 2025
Q3
2025
Sep 30, 2024
($15.51M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($10.99M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($9.62M)
May 6, 2025
Q3
2024
Sep 30, 2023
($9.49M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($8.19M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($17.30M)
May 7, 2024
Q3
2023
Sep 30, 2022
($8.18M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($12.34M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($8.52M)
May 9, 2023
Q3
2022
Sep 30, 2021
($13.88M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($16.70M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($15.41M)
May 10, 2022
Q3
2021
Sep 30, 2020
($33.97M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($38.14M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($29.89M)
May 13, 2021
Q3
2020
Sep 30, 2019
($25.10M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
$1.71M
Aug 31, 2020